Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 232 (7%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3280 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (12%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-ACYCLOVIR OINTMENT | 5% | OINTMENT | Resolved | 2021-11-26 | 2021-12-23 | 150052 |
| APO-ACYCLOVIR OINTMENT | 5% | OINTMENT | Resolved | 2024-12-19 | 2025-08-01 | 246067 |
| APO-ACYCLOVIR OINTMENT | 5% | OINTMENT | Resolved | 2025-03-13 | 2025-08-01 | 252560 |
| APO-ACYCLOVIR OINTMENT | 5% | OINTMENT | Actual shortage | 2025-10-16 | 2025-11-27 | 269754 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2017-03-11 | 2017-06-05 | 633 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2017-05-10 | 2017-07-19 | 9849 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2017-06-19 | 2017-09-03 | 13300 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2017-08-08 | 2017-12-31 | 18512 |
| APO-ALENDRONATE | 5MG | TABLET | Resolved | 2017-10-11 | 2018-03-27 | 25204 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2018-04-04 | 2018-05-24 | 44966 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2018-05-15 | 2018-07-03 | 49415 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2018-07-04 | 2018-10-09 | 54162 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2018-08-27 | 2018-11-26 | 59284 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2019-06-12 | 2019-07-12 | 86271 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2021-07-09 | 2021-09-27 | 142269 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2021-11-22 | 2021-12-01 | 149699 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2022-06-06 | 2022-08-11 | 162080 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2022-07-11 | 2022-08-11 | 164370 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2023-09-07 | 2023-10-20 | 203837 |
| APO-ALENDRONATE/VITAMIN D3 | 70MG 2800UNIT | TABLET | Resolved | 2017-07-17 | 2018-04-06 | 15962 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-LAMIVUDINE | 300MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60560 |
| APO-LAMIVUDINE HBV | 100MG | TABLET | Discontinued | 2018-09-07 | 2019-12-21 | 60563 |
| APO-LATANOPROST-TIMOP | Discontinued | 2018-09-07 | 2018-09-15 | 60572 | ||
| APO-LEVOCARB | 25MG 250MG | TABLET | Discontinued | 2018-09-07 | 2019-02-07 | 60576 |
| APO-LISINOPRIL | 10MG | TABLET | Discontinued | 2018-09-07 | 2019-02-02 | 60579 |
| APO-LISINOPRIL | 20MG | TABLET | Discontinued | 2018-09-07 | 2018-11-26 | 60582 |
| APO-LISINOPRIL | 5MG | TABLET | Discontinued | 2018-09-07 | 2019-02-13 | 60585 |
| APO-LISINOPRIL/HCTZ | 12.5MG 20MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1090 |
| APO-LISINOPRIL/HCTZ | 12.5MG 10MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1093 |
| APO-LISINOPRIL/HCTZ | 25MG 20MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1096 |
| APO-LITHIUM CARBONATE | 300MG | CAPSULE | Discontinued | 2018-09-07 | 2018-09-15 | 60588 |
| APO-LOPERAMIDE | 2MG | TABLET | Discontinued | 2017-03-31 | 2017-03-31 | 4930 |
| APO-LORAZEPAM | 0.5MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60591 |
| APO-LORAZEPAM | 1MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60594 |
| APO-LOSARTAN | 50MG | TABLET | Discontinued | 2018-09-10 | 2018-09-15 | 60987 |
| APO-LOSARTAN | 100MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71213 |
| APO-LOSARTAN | 25MG | TABLET | Discontinued | 2019-02-01 | 2019-02-02 | 74376 |
| APO-LOSARTAN/HCTZ | 12.5MG 100MG | TABLET | Discontinued | 2018-09-07 | 2018-11-02 | 60597 |
| APO-LOSARTAN/HCTZ | 25MG 100MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60600 |
| APO-LOSARTAN/HCTZ | 12.5MG 50MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60603 |